BUZZ-Regenxbio rises after report FDA to reverse rejection of rare-disease gene therapy

REGENXBIO, Inc.

REGENXBIO, Inc.

RGNX

0.00

** Shares of drug developer Regenxbio RGNX.O rise 7.8% to $8.41 premarket

** U.S. FDA to reverse rejection of RGNX's rare-disease gene therapy, Navsunli, Wall Street Journal reports

** Co plans to refile its application in Q3 after a formal meeting with the FDA expected in July, the reports says

** FDA had rejected the initial application in February, citing concerns around the study and asking for a new trial with placebo patients

** Reuters could not immediately reach Regenxbio for comment outside regular business hours

** As of last close, RGNX down 45.8% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.